AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 12 min read$CADL

Tyagarajan Seshu sold $70K of CADL

Tyagarajan Seshu (Chief Technology Officer) sold 7,000 shares of Candel Therapeutics, Inc. (CADL) at $10.02 on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tyagarajan Seshu
Published Jul 1, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CADL
Neutral
medium confidence
Mentioned
$CADL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CADLNeutralLow
01

Why it matters

The newest fact is the specific sale size, price ($10.0216/share), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the disclosed insider sale, but the 10b5-1 structure and modest value suggest limited trading impact.

03

What to watch

The filing doesn’t indicate intent beyond the plan; without context on total planned volume and prior filings, the signal is weak.

Relevance 2/10Novelty 5/10Timing: Filed 2026-07-01; sale executed 2026-06-29.

Background

This is an SEC Form 4 insider transaction disclosure for Candel Therapeutics, Inc. (CADL).

Company-level read

Ticker impact

$CADLNeutralMedium confidence
Context

SEC Form 4 shows CTO Tyagarajan Seshu sold 7,000 CADL shares on 2026-06-29 under a 10b5-1 plan for ~$70.2K.

Expected impact

Likely limited/none; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale by an officer with a pre-arranged 10b5-1 plan and relatively small dollar value versus typical company market caps.

Market effects

Sector

No clear sector read-through from a single, small 10b5-1 sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal risk management or liquidity needs; monitor for follow-on sales beyond planned tranches.

Key entities

  • issuer
    Candel Therapeutics, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Tyagarajan Seshu

    Chief Technology Officer who sold shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that reduces discretionary-signal interpretation.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CADL insider trading history →

Related articles

OCT 22
$CADLMedAI 8/10

Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

investing.com2 min
OCT 2
$CADLHighAI 8/10

H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

investing.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

globenewswire.com3 min